Intensified versus Standard Dose Infliximab Induction Therapy for Steroid-Refractory Acute Severe Ulcerative Colitis (PREDICT-UC): An Open-Label, Multicentre, Randomised Controlled Trial

In this open-label, multicenter, randomized controlled trial, patients aged 18 years or older from 13 Australian tertiary hospitals with intravenous steroid-refractory acute severe ulcerative colitis were randomly assigned to receive a first dose of ten mg/kg infliximab or five mg/kg infliximab.